HR and breast carcinoma: We then classified breast cancer subjects into three groups according to their ER, PR, and HER2 protein expression status, and found that PICH expression was greatly elevated in TNBC tumors compared with hormone receptor (HR)-positive/HER2-negative tumors, and HER2-positive tumors (Fig. 1c, d).